GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (NAS:LXRX) » Definitions » E10

Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) E10 : $-0.82 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Lexicon Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Lexicon Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.200. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.82 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 10.10% per year. During the past 5 years, the average E10 Growth Rate was 14.70% per year. During the past 10 years, the average E10 Growth Rate was 15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Lexicon Pharmaceuticals was 19.90% per year. The lowest was 8.40% per year. And the median was 14.05% per year.

As of today (2024-04-30), Lexicon Pharmaceuticals's current stock price is $1.545. Lexicon Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $-0.82. Lexicon Pharmaceuticals's Shiller PE Ratio of today is .


Lexicon Pharmaceuticals E10 Historical Data

The historical data trend for Lexicon Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals E10 Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.34 -1.13 -0.97 -0.89 -0.82

Lexicon Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -0.88 -0.86 -0.83 -0.82

Competitive Comparison of Lexicon Pharmaceuticals's E10

For the Biotechnology subindustry, Lexicon Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexicon Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's Shiller PE Ratio falls into.



Lexicon Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lexicon Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.2/129.4194*129.4194
=-0.200

Current CPI (Dec. 2023) = 129.4194.

Lexicon Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201403 -0.420 99.695 -0.545
201406 -0.350 100.560 -0.450
201409 -0.550 100.428 -0.709
201412 -0.035 99.070 -0.046
201503 -0.270 99.621 -0.351
201506 -0.270 100.684 -0.347
201509 -0.340 100.392 -0.438
201512 0.760 99.792 0.986
201603 -0.340 100.470 -0.438
201606 -0.370 101.688 -0.471
201609 -0.350 101.861 -0.445
201612 -0.310 101.863 -0.394
201703 -0.330 102.862 -0.415
201706 -0.330 103.349 -0.413
201709 -0.290 104.136 -0.360
201712 -0.270 104.011 -0.336
201803 -0.400 105.290 -0.492
201806 -0.330 106.317 -0.402
201809 -0.260 106.507 -0.316
201812 -0.160 105.998 -0.195
201903 -0.210 107.251 -0.253
201906 -0.220 108.070 -0.263
201909 1.950 108.329 2.330
201912 -0.480 108.420 -0.573
202003 -0.630 108.902 -0.749
202006 -0.650 108.767 -0.773
202009 0.710 109.815 0.837
202012 -0.040 109.897 -0.047
202103 -0.150 111.754 -0.174
202106 -0.130 114.631 -0.147
202109 -0.160 115.734 -0.179
202112 -0.170 117.630 -0.187
202203 -0.160 121.301 -0.171
202206 -0.160 125.017 -0.166
202209 -0.130 125.227 -0.134
202212 -0.160 125.222 -0.165
202303 -0.170 127.348 -0.173
202306 -0.220 128.729 -0.221
202309 -0.210 129.860 -0.209
202312 -0.200 129.419 -0.200

Add all the adjusted EPS together and divide 10 will get our e10.


Lexicon Pharmaceuticals  (NAS:LXRX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Lexicon Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Executives
Philippe Amouyal director C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016
Lonnel Coats director, officer: President and CEO 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Raymond Debbane director, 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022
Thomas Garner officer: SVP, Chief Commercial Officer 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381
Jeffrey L Wade officer: EVP, Gen. Counsel 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Wendy Mcdermott officer: VP, Human Resources 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Artal International S.c.a. director, 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Invus Partners, Llc director, 10 percent owner 750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022
Ulys, Llc director, 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Kiernan Seth officer: VP, Chief Commercial Officer 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kenneth B. Kassler-taub officer: SVP, Regulatory & QA 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kristen Alexander officer: VP, Finance and Accounting 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Craig B Granowitz officer: SVP, Chief Medical Officer 58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960
James F Tessmer officer: VP, Finance & Acctg 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381

Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Headlines

From GuruFocus